Table 1.
Authors | Settings | Design | n | Timing of IGF-I measurement | Age (mean, sd) | Baseline cognitive status | Findings |
---|---|---|---|---|---|---|---|
Wilson et al. [96] | Medical | Cohort | 12 | Baseline | 84.5, 4.2 | *MCI + normal | Low IGF-I risk for incident delirium |
Adamis et al. [30] | Medical | Cross-sectional | 22 | Baseline | 84.6, 6.5 | 50% with dementia + MCI + normal | Association of IGF-I and prevalence delirium |
Lemstra et al. [97] | Orthopaedic | Case Control | 18 | Baseline | 79.3 | *MCI + normal | No association of IGF-I and delirium |
Adamis et al. [98] | Medical | Longitudinal | 28 | Baseline and every 3 days (max 4) | 84.2, 6.3 | 50% with dementia + MCI + normal | Association of IGF-I and all delirium |
Morandi et al. [99] | ICU | Cohort | 40 | Day before assessment of delirium | 65 (median) | No dementia | No association between IGF-I and next-day delirium |
*MCI: Mild cognitive impairment.